Drug Master Files, manufacturer listings, and Electronic Common Technical Document (eCTD) submissions are foundational to regulatory compliance. Yet even experienced regulatory, quality, and operations...
The global Unique Device Identification (UDI) landscape is entering a critical enforcement phase — and 2026 will be a challenging year for medical device manufacturers operating in the European Union...
The FDA’s final rule, “Revising the National Drug Code Format and Drug Label Barcode Requirements,” establishes a uniform 12-digit format for FDA-assigned National Drug Codes (NDCs) ...
UDI product data is now due for specific scenarios (enforced as of December 8, 2022). Class I and Unclassified medical devices that are required to be labeled with a UDI code must submit product data...
LexisNexis Life Sciences Solutions and ONIX expand strategic alliance to guide pharma customers to market faster Professionals in the life sciences industry rely on unique regulatory affairs expertise...
Professionals in the life sciences industry rely on unique regulatory affairs expertise to effectively manage the full end-to-end Electronic Common Technical Document (eCTD) process. LexisNexis Life Sciences Solutions, a leading provider of data management and analytics solutions for the life sciences industry, continues to build an alliance of world-class solution providers, a collective of regulatory experts delivering solutions and services who support manufacturers, distributors and related operations. To strengthen the breadth of pharma eCTD submission solutions, LexisNexis Life Sciences has expanded its collaboration with ONIX, a leading industry expert, serving specialized regulatory processes for clinical trial and drug applications. Current and prospective customers of both companies can leverage exclusive benefits as part of this new strategic alliance.
“ONIX has a world-class track record of servicing clients globally with eCTD services that carry a 100% approval rate with zero eCTD technical rejections since their inception in 2010. The Structured Product Labeling (SPL) expertise of LexisNexis Life Sciences aligned with the global regulatory operations and consulting services provided by ONIX, offer a more streamlined process to support our pharma customers,” said Arshad Rahman, General Manager of the LexisNexis Life Sciences division.
“LexisNexis Life Sciences is the industry leading SPL services provider servicing 1,000+ pharma customers around the world, large and small. Their decades of experience delivering quality files on-time and accurately has garnered LexisNexis Life Sciences a stellar reputation and positioned them as an industry leader in the Life Sciences community. Our customers can undoubtedly benefit from the expertise and guidance provided by their dedicated team of technical specialists in understanding global regulatory submission requirements,” said Jasbir Chohan, CEO of ONIX. “As a result, ONIX is delighted to partner with LexisNexis Life Sciences to offer a comprehensive solution that helps pharma companies bring new products to market and maintain existing portfolios.”
Pharma manufacturers and labelers have obligations to regulators requiring expertise to ensure approvals and speed to market. The complementary solutions and services between LexisNexis Life Sciences and ONIX offer critical efficiency gains in managing the product regulatory approval process.
LexisNexis Life Sciences Solutions helps manufacturers and distributors of medical device and drug products achieve regulatory compliance and improved product data management. For more information, visit LexisNexis Life Sciences.
LexisNexis Legal & Professional® provides legal, regulatory, and business information and analytics that help customers increase their productivity, improve decision-making, achieve better outcomes, and advance the rule of law around the world. As a digital pioneer, the company was the first to bring legal and business information online with its Lexis® and Nexis® services. LexisNexis Legal & Professional, which serves customers in more than 150 countries with 10,500 employees worldwide, is part of RELX, a global provider of information-based analytics and decision tools for professional and business customers.
ONIX is a global regulatory operations and advice consulting group. The team has over 60 years of experience in supporting Pharma, Biotech, Universities, Contract Research Organization (CRO) and Pharma Venture Capital companies throughout the regulatory approval processes for drugs, herbal, veterinary and medical devices with their respective Regulatory Health Authorities. ONIX has supported more than 100 clients across Europe, North America, South America, Middle East and Asia Pacific throughout the process from initial clinical trials application to full marketing approvals and lifecycle maintenance. For more information, visit www.onixls.com.
Contact us